Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Giampaolo Perri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2072-7114; OpenAlex author ID A5008305260. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 7, last author 0)
Trials
1
Grants
0
Labs led
0
Collaborators
70
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 6 papers · 2021: 4 papers · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 3 papers, 1 trial · 2026: 8 papers

Papers 26

  1. The projected rise of pancreatic cancer mortality in Italy: forecasts until 2035. First author DOI 10.1007/s13304-026-02862-w↗
  2. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  3. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… Co-author DOI 10.1016/j.surg.2026.110302↗
  4. Proposal for an Objective and Concrete Definition for Determining Anatomic Resectability in Pancreatic Cancer: The Concept of the "Suitable Target". Co-author DOI 10.1097/xcs.0000000000001738↗
  5. Conversion surgery vs. standard of care in pancreaTic cancer oligometastatic to the liver (SONAR: Surgery in Oligometastatic paNcreatic cAnceR) a randomized co… First author DOI 10.1186/s12885-025-15183-9↗
  6. Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with… First author DOI 10.1245/s10434-026-19939-w↗
  7. ASO Visual Abstract: Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapie… First author DOI 10.1245/s10434-026-19987-2↗
  8. ASO Author Reflections: Local Therapy for Single-Site Recurrent Pancreatic Cancer: Anatomy, Biology, and Selection. First author DOI 10.1245/s10434-026-20012-9↗
  9. Complications following upfront pancreatectomy with venous resection do not compromise adjuvant chemotherapy delivery and survival in pancreatic cancer. Co-author DOI 10.1007/s00423-025-03933-z↗
  10. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  11. Introducing 'borderline observable' intraductal papillary mucinous neoplasms: between pancreatic cancer risk and discontinuation of extended surveillance. Co-author DOI 10.1136/gutjnl-2025-334807↗
  12. Simulation Model of Pancreatic Cancer Precursors Progression: "Timely" Surgery Does Not Equal "Opportune" (Anymore). Co-author DOI 10.1053/j.gastro.2023.09.037↗
  13. The Importance of Reading the Skin: Cutaneous Metastases of Pancreatic Cancer, a Systematic Review. Co-author DOI 10.3390/jcm13010104↗
  14. The prognostic role of fatigue, depression and anxiety on postoperative outcomes after pancreatectomy for pancreatic cancer. A prospective observational study … First author DOI 10.1016/j.pan.2022.10.001↗
  15. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. First author DOI 10.6004/jnccn.2022.7018↗
  16. Neoadjuvant Chemotherapy in Pancreatic Cancer-Reply. Co-author DOI 10.1001/jamasurg.2020.6279↗
  17. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  18. Response to the Comment on "Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma". Co-author DOI 10.1097/sla.0000000000003987↗
  19. Neoadjuvant therapy in resectable pancreatic cancer-is this the way forward?-a narrative review. Co-author DOI 10.21037/cco-21-51↗
  20. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2020.2286↗
  21. Defining and Treating Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1007/s11864-020-00769-1↗
  22. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003763↗
  23. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08427-4↗
  24. ASO Author Reflections: The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancr… Co-author DOI 10.1245/s10434-020-08531-5↗
  25. Response to Preoperative Therapy in Localized Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00516↗
  26. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.hpb.2017.10.017↗

Trials 1

  1. Early Recurrence After Surgery for Pancreatic Cancer Study director NCT07241676↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giovanni Marchegiani · 13 shared papers, 1 shared trial, 2018–2026 · strength 4.49
  2. Matthew H. G. Katz · 10 shared papers, 2020–2022 · strength 1.69
  3. Umberto Cillo · 6 shared papers, 2023–2026 · strength 1.65
  4. Aya Maekawa · 3 shared papers, 2026 · strength 1.03
  5. Laura R. Prakash · 7 shared papers, 2020–2022 · strength 0.89
  6. Samuele Grandi · 3 shared papers, 2025–2026 · strength 0.87
  7. Roberto Salvia · 5 shared papers, 2018–2026 · strength 0.75
  8. Alessio Marchetti · 3 shared papers, 2025–2026 · strength 0.69
  9. Greg D. Sacks · 3 shared papers, 2025–2026 · strength 0.69
  10. Agata Grochowska · 2 shared papers, 2026 · strength 0.60
  11. Jonathan Garnier · 2 shared papers, 2026 · strength 0.52
  12. Michael D. Kluger · 2 shared papers, 2026 · strength 0.52
  13. Christopher Lee Wolfgang · 2 shared papers, 2026 · strength 0.52
  14. Naruhiko Ikoma · 5 shared papers, 2020–2022 · strength 0.52
  15. Michael P. Kim · 5 shared papers, 2020–2022 · strength 0.52
  16. Jeffrey E. Lee · 5 shared papers, 2020–2022 · strength 0.52
  17. Ching-Wei David Tzeng · 5 shared papers, 2020–2022 · strength 0.52
  18. Riccardo Guastella · 2 shared papers, 2025–2026 · strength 0.49
  19. Michael James Overman · 4 shared papers, 2020–2022 · strength 0.43
  20. Milind M. Javle · 4 shared papers, 2020–2022 · strength 0.43
  21. Robert A. Wolff · 4 shared papers, 2020–2022 · strength 0.43
  22. Ingmar Florin Rompen · 2 shared papers, 2025–2026 · strength 0.40
  23. Joseph R. Habib · 2 shared papers, 2025–2026 · strength 0.40
  24. Paul C. M. Andel · 2 shared papers, 2025–2026 · strength 0.40
  25. Ammar A. Javed · 2 shared papers, 2025–2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.